Lehane Consulting Ltd are celebrating our 1 year anniversary! We launched our services in 2023 and have enjoyed a fantastic first year of building our network, sharing our skills and welcoming new customers. To mark our birthday in style, we would like to offer One Nucleus members the opportunity for a 20 minute introductory call - to meet, engage and explore the potential of new projects in 2024.
Drop an email to Lucy@Lehaneconsulting.co.uk quoting #YearOneNucleus
About Lehane Consulting Ltd
With over 25 years' of expertise in the IVD Industry, we are dedicated to helping…
We are delighted to share the results from Aon's 2023 Global Risk Management Survey (GRMS).
The GRMS collects and analyses business leaders' assessment of risk and risk management. The 2023 report is the ninth edition of the survey and the results from both Global and UK respondents reflect the increasingly interconnected nature of risk, with traditional business risks and people risks converging to create significant challenges for organisations.
GRMS survey findings for the Life Sciences industry ranked supply chain or distribution failure, and cyber-attack or data breach as their two most…
Delivery across the business leaves Arecor in strong position
Continued momentum in diabetes portfolio with AT278 clinical trial on track for key data readout in H1 2024
First commercial launch of Arestat™ enabled product licensed to partner, AT220, triggering milestone payment and now generating royalties
Further expansion of partnership portfolio and licensing of products incorporating Arestat™ technology
Continued success of Ogluo® commercialisation increasing Tetris Pharma product sales to £2.9 million (2022: £1.1 million)
Total Group revenue of £4.6 million (2022: £2.4…
Aon – Life Science Sector Specific Employee Benefits Survey:
Participating in this targeted survey can give you unique data insight to help:
Benchmark against your industry and non-industry competition to support attraction and retention of talent.
Create a business case backed by data to justify positive benefit changes in your organisation.
Why should organisations participate in this survey?
Aon’s Life Science specific benefits benchmarking survey provides a unique opportunity for organisations to use our data insights to understand how they measure up to their competitors…
The Cambridge Wide Open Day event on Wednesday 12th June is a unique opportunity for all to find out firsthand about the game-changing scientific advancements and technological innovations happening right here in our city, the UK’s science and tech capital.
The cream of Cambridge science and technology is opening its doors to participate in this year’s Be Curious event across the four main science clusters located in:
· Cambridge North including Allia Future Business Kings Edge, Cambridge Science Park, St John’s Innovation Centre, Co-Laboratories, and…
Produced using dry-spun 50 µm Collagen Type I fibers, AMSBIO has introduced the innovative CollaFibR™ additive proven to increase the shape fidelity and biological relevance of bioprinted constructs in hydrogels and bioinks.
In the field of personalized tissue engineering, 3D bioprinting shows immense promise, but the challenge lies in achieving both mechanical durability and biological relevance in the printed constructs.
Acting as a physiologically relevant site for cell attachment within constructs - μCollaFibR™ has been shown to improve the…
SALT LAKE CITY, US and OXFORD, UK – 13 May 2024 – The leading US multi-specialty healthcare center, Metrodora Institute, and pioneering precision medicine company, PrecisionLife, announce the start of recruitment on a cohort of up to 1,000 patients into clinical trials to evaluate new diagnosis and treatment options for ME/CFS, Long Covid, and related disorders. The partners have developed genotypic diagnostic tests that are now being evaluated for their ability to provide clinicians with an accurate view of a patient’s risk of a specific disease. Ultimately, using the molecular profile of…
Arecor Therapeutics plc
(“Arecor” or the “Company”)
ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY
- Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump
Cambridge, UK, 9 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announced a research collaboration with Medtronic plc (NYSE: MDT), a…
DISCOVERY PARK BUSINESS A4P RECEIVES THE KING’S AWARD FOR ENTERPRISE IN INTERNATIONAL TRADE
The most prestigious business award in the United Kingdom.
May 8, 2024, Discovery Park, Sandwich, Kent: A4P, A LabConnect Company, based at Discovery Park, an international centre for science and innovation, in Kent, has been honoured with a King’s Award for Enterprise for International Trade. A4P is one of 252 organisations nationally recognised with a prestigious King’s Award for Enterprise, across four categories - International Trade, Innovation, Sustainable Development and Promoting…
A new report released today by Medicines Discovery Catapult (MDC), in partnership with the UK BioIndustry Association and the Association of the British Pharmaceutical Industry, highlights the impact of recent economic instability on companies in the life sciences sector.
The future health of patients depends on continuing to improve approaches to medicines discovery. However, barriers to investing in companies in the current economic climate threaten to prevent the UK from making some of its biggest breakthroughs.
State of the Discovery Nation (SODN) 2024: ‘Fostering a Dynamic, Sustainable…